Development and Validation of a Rapid HPLC-DAD Method for Determination of Favipiravir in Pharmaceutical Formulation

Objective: The aim of this work was to develop and validate a rapid and simple high-performance liquid chromatography method with a diode- array detector (HPLC-DAD) for determination of favipiravir in bulk and tablet formulations. Methods: The chromatographic analysis was performed at 30 °C with a Poroshell 120EC-C18 column (4.6 x 50 mm, 2.7 µm). The mobile phase was a mixture of 0.1% formic acid in water and 0.1% formic acid in acetonitrile (90:10, v/v). The run time was 5 min at a flow rate of 0.5 mL/min. Results: The proposed method was successfully validated in terms of precision, accuracy, linearity, robustness, limits of detection (LOD) and quantification (LOQ) parameters. The calibration plot was linear over a concentration range of 10-100 µg/mL. The LOD and LOQ values were found to be 0.58 µg/mL and 2.03 µg/mL, respectively. The average recovery values were found to vary from 99.45 percent to 104.29 percent. Conclusion: As a result, it was concluded that the developed method can be used successfully in the determination of favipiravir in pharmaceutical preparations.

Keywords:

COVID-19 treatment, HPLC, validation, favipiravir SARS-CoV-2,

PDF

___

[1] Ibraam EM, Heba E, Fathalla B, Adel EI. Green micellar solvent- free HPLC and spectrofluorimetric determination of favipiravir as one of COVID-19 antiviral regimens Microchemical Journal 2021;165 (2021): 106189.
[2] Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease, (COVID-19): A review. JAMA 2020; 324 (2019): 782–793.
[3] Acquavia A, Foti L, Pascale R, Nicolo A, Brancaleone V, Cataldi TR. Detection and quantification of Covid-19 antiviral drugs in biological fluids and tissues. Talanta. 2021; 224 (2021):121862.
[4] Delang L; Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018; 153: 85–94.
[5] China patent (CN104914185A). HPLC method for measuring related substances in Favipiravir. 16.09.2015.
[6] Madelain JG, Nguyen THT, Jacquot F, Oestereich L, Kadota T. Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses, Antimicrob. Agents Chemother.2017; 61 (1): (2017), https://doi.org/10.1128/AAC.01305-16.
[7] Smee DF, Hurst BL, Egawa H, Takahashi, K, Kadota T, Furuta Y. Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virusinfected cells, J. Antimicrob. Chemother. 2009;64 (2009): 741–746.
[8] Nguyen THT, Guedj J, Anglaret X, Laou´enan C, Madelain V, Taburet AM. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted, PLoS Negl. Trop. Dis. 2017;11 (2): e0005389.
[9] Gowen BB, Sefing EJ, Westover JB, Smee, DF, Hagloch J, Furuta Y, et al., Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. Antiviral Res. 2015;121 (2015): 132–137.
[10] Safa MM, Ahmed A H, Sherin F H, Amira H. Kamal Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: Application to spiked human plasma Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy.2021; 249 (2021): 119241
[11] Nguyen THT, Guedj J, Anglaret X, Laou´enan C, Madelain V, Taburet AM. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted, PLoS Negl. Trop. Dis. 2017;11 (2): e0005389.
[12] A kind of Favipiravir has the HPLC assay method of related substance, Google Patents, CN104914185B (2015) Chinese article.
[13] Bulduk I. HPLC-UV method for quantification of favipiravir in pharmaceutical formulations, Acta Chromatographica. 2020; 1-7, DOI: 10.1556/1326.2020.00828.
[14] ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology.; 2018 July 7. Available from: http://www. ema.europa.eu/docs/en_GB/document_library /Scientific_ guideline/2009/09/WC500002662.pdf [Website].